Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB.
Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-daily tablet of V5 or placebo for one month in addition to conventional anti-TB therapy (ATT) administered under directly observed therapy (DOT).The enlarged liver, total bilirubin, erythrocyte sedimentation rate, lymphocyte and leukocyte counts improved significantly in V5 recipients (P = 0.002; 0.03; 8.3E-007; 2.8E-005; and 0.002) but remained statistically unchanged in the placebo group (P = 0.68; 0.96; 0.61; 0.91; and 0.43 respectively). The changes in hemoglobin and ALT levels in both treatment arms were not significant. The body weight increased in all V5-treated patients by an average 3.5 ± 1.8 kg (P = 2.3E-009), while 6 out of 10 patients on placebo gained mean 0.9 ± 0.9 kg (P = 0.01). Mycobacterial clearance in sputum smears was observed in 78.3% and 0% of patients on V5 and placebo (P = 0.009). The conversion rate in V5-receiving subjects with MDR-TB (87.5%) seemed to be higher than in first-diagnosed TB (61.5%) but the difference was not significant (P = 0.62). Scoring of sputum bacillary load (range 3-0) at baseline and post-treatment revealed score reduction in 23 out of 24 (95.8%) V5 recipients (from mean/median 2.2/3 to 0.3/0; P = 6E-010) but only in 1 out of 10 (10%) patients on placebo (1.9/1.5 vs. 1.8/1; P = 0.34). No adverse effects or TB reactivation were seen at any time during follow-up. V5 is safe as an immune adjunct to chemotherapeutic management of TB and can shorten substantially the duration of treatment.
Department of Phtysiatry and Pulmonology, Kharkov National Medical University; Kharkov, Ukraine. zaitzeva@list.ru.
Dmitry A
DA
Butov
Yuri N
YN
Pashkov
Anna L
AL
Stepanenko
Aleksandra I
AI
Choporova
Tanya S
TS
Butova
Dendev
D
Batdelger
Vichai
V
Jirathitikal
Aldar S
AS
Bourinbaiar
Svetlana I
SI
Zaitzeva
Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52
17021358
Probl Tuberk Bolezn Legk. 2006;(5):45-8
16850924
Indian J Tuberc. 2010 Apr;57(2):67-74
21114172
Probl Tuberk. 2002;(3):21-5
12066527
Probl Tuberk Bolezn Legk. 2005;(3):43-6
15945453
Front Biosci. 2004 May 01;9:1701-19
14977580
Respirology. 2010 Apr;15(3):433-50
20415982
Am J Respir Crit Care Med. 2006 Aug 1;174(3):236-7
16864715
Vaccine. 2006 Jan 16;24(3):280-6
16153758
Vaccine. 2008 May 23;26(22):2733-7
18455842
Yale J Biol Med. 2010 Dec;83(4):209-15
21165340
Am J Clin Pathol. 1957 Jul;28(1):56-63
13458125
Clin Microbiol Infect. 2009 Dec;15(12):1154-62
19456829
BMJ. 2010 Mar 15;340:c671
20231251
Expert Opin Drug Deliv. 2007 Jul;4(4):323-40
17683247
Indian J Tuberc. 2009 Jan;56(1):5-9
19402266
Clin Exp Immunol. 2006 Aug;145(2):252-60
16879244
Infect Immun. 2002 Jul;70(7):3318-23
12065468
Kekkaku. 2010 Nov;85(11):777-82
21174733
Vaccine. 2008 Nov 11;26(48):6092-8
18809446
Infect Immun. 2002 Apr;70(4):2100-7
11895976
J Exp Med. 2010 Aug 2;207(8):1609-16
20624887
Zhonghua Yu Fang Yi Xue Za Zhi. 2008 Feb;42(2):86-9
18642658
Vaccine. 2010 Jan 22;28(4):1106-16
19853680
Clin Chest Med. 2009 Dec;30(4):769-82, ix
19925966
Nat Med. 2000 Sep;6(9):955-60
10973302
Immunotherapy. 2011 Feb;3(2):181-91
21182457
Bull World Health Organ. 2008 Feb;86(2):147-54
18297170
Clin Microbiol Infect. 2007 Feb;13(2):129-138
17328724
Curr Pharm Des. 2009;15(11):1159-71
19355957